- •Preface to the Second Edition
- •Contents
- •List of Abbreviations
- •1: Epidemiology of AMD
- •Core Messages
- •1.1 Introduction
- •1.3 Frequency
- •1.3.1 Prevalence
- •1.3.2 Incidence
- •1.4 Natural Course
- •1.5 Genetic Factors
- •1.5.1 The Complement Pathway Genes
- •1.5.1.1 Complement Factor H (CFH)
- •1.5.1.3 Complement Component 3 (C3)
- •1.5.1.4 Complement Factor I (CFI)
- •1.5.2 The ARMS2 (10q26) Locus
- •1.5.3.1 Apolipoprotein E (APOE)
- •1.5.4 Candidate Gene Association Studies
- •1.6 Environmental Factors
- •1.6.1 Smoking
- •1.6.2 Antioxidants
- •1.6.3 Body Mass Index (BMI)
- •1.6.4 Hypertension
- •1.6.5 Cataract Surgery
- •1.7 Interaction Between Risk Determinants
- •1.7.1 Combined Effects of CFH Y402H and Other Genetic and/or Environmental Factors
- •1.7.2 Combined Effects of 10q26 SNPs and Other Genetic and/or Environmental Factors
- •1.7.4 Combined Effects of the APOE Gene and Other Genetic and/or Environmental Factors
- •References
- •2: Genetics
- •Core Messages
- •2.1 Introduction
- •2.2 Identifying Risk Factors of a Common Disease
- •2.3 Early Findings
- •2.4.1 Functional Implications
- •2.5.1 Functional Implications
- •2.7 Prospects of Genetics in AMD Therapy and Prevention
- •Summary for the Clinician
- •References
- •Core Messages
- •3.1 Introduction
- •3.2 Cause and Consequences of Ageing
- •3.3 Clinical Changes Associated with Retinal Ageing
- •3.4 Ageing of the Neural Retina
- •3.5 Ageing of the RPE
- •3.5.1 Changes in RPE Cell Density
- •3.5.2 Subcellular Changes in the RPE
- •3.5.3 Accumulation of Lipofuscin
- •3.5.4 Melanosomes and Pigment Complexes
- •3.5.7 Antioxidant Capacity of the RPE
- •3.6 Ageing of Bruch’s Membrane
- •3.7 The Association Between Ageing and AMD
- •Summary for the Clinician
- •References
- •Core Messages
- •4.1 Introduction
- •4.2 The Complement System
- •4.3 Evidence for Involvement of the Complement System in AMD Pathogenesis
- •4.4.2 Complement Gene Variants and AMD Subtypes
- •4.4.3 Complement Gene Variants and Progression of AMD
- •4.4.5 Variations of Complement Genes and Response to Treatment: Pharmacogenetics
- •4.5 Emerging Pharmacological Intervention Targeting Complement Dysregulation
- •Conclusions
- •Summary for the Clinician
- •References
- •5: Histopathology
- •Core Messages
- •5.1 Retinal Pigment Epithelium
- •5.1.1 Structure and Function of the Retinal Pigment Epithelium
- •5.1.3 Deposits in the RPE
- •5.2 Bruch’s Membrane
- •5.2.1 Structure of Bruch’s Membrane
- •5.2.3 Deposits in Bruch’s Membrane, Drusen
- •5.3 Choroidal Neovascularization
- •5.4 Detachment of the Retinal Pigment Epithelium
- •5.5 Geographic Atrophy of the RPE
- •Summary for the Clinician
- •References
- •6: Early AMD
- •Core Messages
- •6.1 Introduction
- •6.2 Drusen
- •6.2.3 Fluorescence Angiography and Optical Coherence Tomography
- •6.3 Focal Hypopigmentation and Hyperpigmentation of the Retinal Pigment Epithelium
- •6.4 Abnormal Choroidal Perfusion
- •Summary for the Clinician
- •References
- •Core Messages
- •7.1 Introduction
- •7.2.1 Decreased Visual Acuity
- •7.2.2 Visual Distortion
- •7.2.3 Visual Field Defects
- •7.2.4 Miscellaneous Symptoms
- •7.3 Signs of Choroidal Neovascularization
- •7.3.1 Hemorrhage
- •7.3.2 Macular Edema and Subretinal Fluid
- •7.3.3 Retinal Pigment Epithelial Detachment
- •7.3.4 Miscellaneous Signs
- •7.4 Common Testing Modalities to Diagnose Choroidal Neovascularization
- •7.4.1 Fluorescein Angiography
- •7.4.2 Indocyanine Green Angiography
- •7.4.4 Optical Coherence Tomography
- •Summary for the Clinician
- •References
- •8: Geographic Atrophy
- •Core Messages
- •8.1 Introduction
- •8.3 Histology and Pathogenesis of Geographic Atrophy
- •8.5 Spectral Domain Optical Coherence Tomography in Geographic Atrophy
- •8.7 Risk Factors
- •8.7.1 Genetic Factors
- •8.7.2 Systemic Risk Factors
- •8.7.3 Ocular Risk Factors
- •8.8 Development of CNV in Eyes with GA
- •8.9 Visual Function in GA Patients
- •8.9.1 Measurement of Visual Acuity
- •8.9.2 Contrast Sensitivity
- •8.9.3 Reading Speed
- •8.9.4 Fundus Perimetry
- •8.10 Perspectives for Therapeutic Interventions
- •8.10.2 Complement Inhibition
- •8.10.3 Neuroprotection
- •8.10.4 Alleviation of Oxidative Stress
- •8.10.5 Serotonin-1A-Agonist
- •8.10.6 Perspective
- •Summary for the Clinician
- •References
- •9: Fundus Imaging of AMD
- •Core Messages
- •9.1 Introduction
- •9.2 Color Photography
- •9.3 Monochromatic Photography
- •9.5 Optical Coherence Tomography
- •9.5.2 Coherence Length
- •9.5.3 Time Domain Optical Coherence Tomography
- •9.5.4 Frequency Domain Optical Coherence Tomography
- •9.5.5 Increasing Depth of Imaging
- •9.5.6 General Optical Coherence Tomographic Imaging Characteristics of the Macular Region
- •9.6 Fundus Angiography
- •9.6.1 Fluorescein Dye Characteristics
- •9.6.2 Indocyanine Green Dye Characteristics
- •9.6.3 Cameras Used in Fluorescence Angiography
- •9.6.4 Patient Consent and Instruction
- •9.6.5 Fluorescein Injection
- •9.6.6 Fluorescein Technique
- •9.6.7 Indocyanine Green Technique
- •9.7 Fluorescein Angiographic Interpretation
- •9.7.1 Filling Sequence
- •9.7.2 The Macula
- •9.8 Deviations from Normal Angiographic Appearance
- •9.10.1 Drusen
- •9.12 Neovascular AMD
- •9.13 Retinal Pigment Epithelial Detachments
- •9.14 Retinal Vascular Contribution to the Exudative Process
- •9.15 Follow-up
- •9.15.1 Thermal Laser
- •9.15.2 Photodynamic Therapy
- •9.15.3 Anti-VEGF Therapy
- •Summary for the Clinician
- •References
- •10: Optical Coherence Tomography
- •10.1 Introduction
- •Core Messages
- •10.4 OCT in Geographic Atrophy
- •10.5 OCT in Exudative AMD
- •Summary for Clinician
- •References
- •11: Microperimetry
- •Core Messages
- •11.1 Introduction
- •11.2.1 From Manual to Automatic Microperimetry
- •11.2.2 Automatic Microperimetry
- •11.2.3 Microperimetry: The Examination
- •11.2.4 Microperimetry: Test Evaluation
- •11.2.5 Other Microperimeter
- •11.3 Microperimetry in AMD
- •11.3.1 Early AMD
- •11.3.2 Geographic Atrophy
- •11.3.3 Neovascular AMD
- •11.3.4 Neovascular AMD: Treatment
- •Summary for the Clinician
- •References
- •Core Messages
- •12.1 Introduction
- •12.2 Antioxidants and Zinc
- •12.3 Beta-Carotene
- •12.4 Macular Xanthophylls
- •12.6 Vitamin E
- •12.7 Vitamin C
- •12.8 Zinc
- •12.10 AREDS2
- •Summary for the Clinician
- •References
- •Core Messages
- •13.1 Introduction
- •13.2 Basic Principles
- •13.2.1 Clinical Background
- •13.2.2 Laser Photocoagulation
- •13.2.3 Photodynamic Therapy
- •13.3 Treatment Procedures
- •13.3.1 Laser Photocoagulation
- •13.3.2 Photodynamic Therapy
- •13.4 Study Results
- •13.4.1 Laser Photocoagulation
- •13.4.1.1 Extrafoveal CNV
- •13.4.1.2 Subfoveal CNV
- •13.4.1.3 Meta-analysis
- •13.4.2 Photodynamic Therapy
- •13.4.2.1 Predominantly Classic
- •13.4.2.2 Occult with No Classic Neovascularization
- •13.4.2.3 Minimally Classic
- •13.5 Safety and Adverse Events
- •13.5.1 Laser Photocoagulation
- •13.5.2 Photodynamic Therapy
- •13.6 Variations
- •13.6.1 Laser Photocoagulation: Different Wavelengths
- •13.6.2 Photodynamic Therapy
- •13.6.3 Combination Treatments
- •13.7 Present Guidelines
- •13.7.1 Laser Photocoagulation
- •13.7.2 Photodynamic Therapy
- •13.8 Perspectives
- •Summary for the Clinician
- •References
- •Core Messages
- •14.1 Introduction
- •14.2 Vascular Endothelial Growth Factor (VEGF)
- •14.3 Targets Within the VEGF Pathway
- •14.3.1 Sequestration of Released VEGF
- •14.3.2 Inhibition of VEGF and VEGF Receptor Synthesis by Small Interfering RNA (siRNA)
- •14.3.3 Inhibition of the Intracellular Signal Cascade
- •14.3.4 Natural VEGF Inhibitors
- •14.4 New Methods of Drug Delivery
- •14.5 Combined Strategies
- •Summary for the Clinician
- •References
- •Core Messages
- •15.1 Introduction
- •15.1.1 Anti-VEGF Therapies for NV-AMD
- •15.2.1 How Should Neovascular AMD be Diagnosed?
- •15.2.4.1 Results with Continuous Monthly Treatment
- •15.2.4.2 How Should Treatment be Started?
- •15.2.4.3 What Flexible Approaches Are Reported?
- •Fixed Quarterly Injection Studies
- •Flexible Dosing Regimens: Two Approaches
- •Flexible Dosing Regimens: ‘As Needed’ Approach
- •Flexible Dosing Regimens: ‘Treat-and-Extend’ Approach
- •Summary for the Clinician
- •References
- •Core Messages
- •16.1 Introduction
- •16.3 Current Limitation of Therapy in the Treatment of Exudative AMD
- •16.4 Rationale for Combination Therapy in the Treatment of Exudative AMD
- •16.5 Clinical Data Examining Combination Therapy for Exudative AMD
- •16.5.3 Triple Therapy for Exudative AMD
- •16.5.4 Combination Therapy with Radiation
- •Summary for the Clinician
- •References
- •Core Messages
- •17.1 Introduction
- •17.2 Current Treatment Options for Dry AMD
- •17.3 Targeting the Cause of AMD
- •17.4 Preclinical and Phase I Drugs in Development for Dry AMD
- •17.4.1 Clinical Trial Endpoints in Dry AMD
- •Trimetazidine
- •17.4.2.2 Neuroprotection
- •Ciliary Neurotrophic Factor (CNTF/NT-501)
- •AL-8309B (Tandospirone)
- •Brimonidine Tartrate Intravitreal Implant
- •17.4.2.3 Visual Cycle Modulators
- •Fenretinide
- •17.4.2.4 Other
- •17.4.3 Drugs to Prevent Injury from Oxidative Stress and Micronutrient Depletion
- •17.4.4.1 Complement Inhibition at C3
- •17.4.4.2 Complement Inhibition at C5
- •Eculizumab
- •17.4.4.3 Complement Inhibition of Factor D
- •FCFD4514S
- •Iluvien
- •Glatiramer Acetate (Copaxone)
- •17.5 Summary
- •Summary for the Clinician
- •References
- •18: Surgical Therapy
- •Core Messages
- •18.1 Maculoplasty
- •18.2 Macular Translocation
- •18.3 Single Cell Suspensions
- •18.5 Indications for Surgery
- •18.5.1 Non-responder
- •18.5.2 Pigment Epithelium Rupture
- •18.5.3 Massive Submacular Bleeding
- •18.5.5 Macula Dystrophies
- •Summary for the Clinician
- •References
- •19: Reading with AMD
- •Core Messages
- •19.1 Introduction
- •19.2 Physiological Principles
- •19.3 Reading with a Central Scotoma
- •19.3.1.2 The Reading Visual Field Related to the Fundus (Fig. 19.4b)
- •19.3.1.3 The Reading Visual Field Related to the Text (Fig. 19.4c)
- •19.3.1.4 Eccentric Fixation Related to the Globe (Fig. 19.5)
- •19.3.3 Examination of Fixation Behaviour
- •19.3.4 Motor Aspects
- •19.4 Methods to Examine Reading Ability
- •19.5 Rehabilitation Approaches to Improve Reading Ability
- •Summary for the Clinician
- •References
- •20: Low Vision Aids in AMD
- •Core Messages
- •20.2 Effects of Visual Impairment in AMD
- •20.5 Optical Magnifying Visual Aids for Distance
- •20.5.1 Aids for Watching Television
- •20.8 Electronic Reading Instruments
- •20.9 Additional Aids
- •20.10 Noteworthy Details for the Provision of Low Vision Aids
- •20.11 Basic Information on Prescription
- •Summary for the Clinician
- •References
- •Index
9 Fundus Imaging of AMD |
149 |
|
|
9.6.7Indocyanine Green Technique
The dye injection for indocyanine green angiography is similar to that done for fluorescein angiography. The photographer should be ready to record images fairly soon after injection, because the choroidal vessels fill before the retinal vessels. Midphase photographs are taken at two different time points – one around 5 min and the second about 10 min after injection. Late phase photographs are taken about 30 min after injection. Generally, scanning laser systems record the filling phases with greater temporal resolution than do fundus camera systems. On the other hand, late phase photographs are better imaged with fundus cameras.
9.7Fluorescein Angiographic Interpretation
In serum, about 80% of the fluorescein is bound to protein and 20% is unbound; the binding alters the absorption and emission spectra slightly. The unbound fluorescein is freely diffusible. It is normally restricted in its diffusion by the blood ocular barrier, which is a combination of two separate anatomical boundaries controlling the flow of solutes and fluid into the eye. The outer portion of the blood ocular barrier is formed by the retinal pigment epithelium. The inner portion of the blood ocular barrier is formed by the walls of the retinal vessels.
9.7.1Filling Sequence
The larger choroidal vessels start to fluoresce first, about 1 s before the retinal arterioles. With fluorescein angiography, the retina circulation is easier to appreciate because it exists largely in two dimensions, it fills from one central point, and it lies over the pigmented RPE which provides a contrasting background. The initial phase of fluorescein filling is called either the “early phase” or the “arterial phase.” The dye front quickly moves through the retinal vessels, but the photographer may be able to demonstrate the dye front moving through the retinal arteriolar system in one of the early fluorescein frames. Successively smaller retinal arterioles fill as the dye front approaches the capillary bed. When the dye front reaches the capillaries, the retinal fluorescence suddenly increases with a blush of luminescence, this time from the retina. While it is not possible to see the vessels of the choriocapil-
laris, it is easy to see individual perifoveal capillaries in a patient with no media opacities.
The dye front then reaches the post-capillary venules and then the larger veins. This trip occurs within a few seconds in a healthy individual, but in an elderly person, the artery-to-vein time may be increased. The dye bolus eventually leaves the eye, and for a few seconds, the total fluorescence from the fundus appears to decrease somewhat. Shortly later, the bolus of dye recirculates through the body and reappears in the ocular circulation. With the reappearance of the dye, the fundus fluorescence increases somewhat. The stage of the angiogram within a minute after injection of dye is sometimes referred to as the recirculation phase. The recirculation phase is readily evident to the photographer or when looking at a video playback from a scanning laser ophthalmoscope, but is less evident when looking at still pictures. Images taken 1–3 min after injection are commonly referred to as midphase photographs. The total fluorescence, though, decreases with time as the dye is removed from the blood stream. After about 5 min or so, the fundus is much darker than after the initial injection of dye. This stage is considered to be the late phase of the angiogram.
9.7.2The Macula
The macular area has a unique pattern of fluorescence as determined by its anatomy. During the fluorescein angiogram, the fovea appears darker than the surrounding areas for several reasons. The fovea itself is avascular, and so, no retinal capillary blush occurs. The macula appears yellow because xanthophyll pigment absorbs shorter wavelengths of light, reducing any excitation of fluorescein dye. The retinal pigment cells in the macular region are taller and have more melanin pigments than the retinal pigment epithelial cells elsewhere, and therefore, both the excitation and the resultant fluorescent light from the underlying choroidal vessels are reduced.
9.8Deviations from Normal Angiographic Appearance
Hyperfluorescence is when there is an excess of fluorescence, either because an excess of angiographic dye is present in any unit volume of the fundus, or because our visualization of the fluorescent material is enhanced. Under normal circumstances, the presence of melanin in the choroid and retinal pigment epithelium and the presence of xanthophyll pigment in the macula form an
150 |
R.F. Spaide |
|
|
Table 9.1 Fluorescein hyperfluorescence characteristics associated with age-related macular degeneration
Transmitted |
RPE thinning, atrophy or depigmenta- |
fluorescence |
tion, RPE rip |
Abnormal vessels |
CNV |
Leakage |
CNV directly into the subretinal space, |
|
leakage through the RPE |
Pooling |
Neurosensory detachment, cystoid |
|
macular edema |
Staining |
Scars, “brushfire” staining at borders of |
|
atrophy |
the increased penetration through melanin in the RPE and choroid, blood and exudation, indocyanine green frequently can show details of vascular structures in the choroid not apparent during fluorescein angiography. One variant of choroidal neovascularization, polypoidal choroidal vasculopathy, has a distinctive appearance in indocyanine green angiography. There are vascular channels with aneurysmal dilations at the outer border of the vascular lesion.
Table 9.2 Fluorescein hypofluorescence characteristics associ- 9.10 Non-Neovascular AMD ated with age-related macular degeneration
Blocked retinal fluorescence |
Vitreous or retinal hemorrhage |
Blocked choroidal |
Hemorrhage |
fluorescence |
RPE hyperplasia |
|
RPE hypertrophy |
|
RPE reduplication secondary |
|
to rip |
Vascular filling defects |
Occlusion of a vascular bed |
impediment to our visualization of choroidal fluorescence. A decrease in any of these factors would allow for a greater transmission of fluorescence to be visible, and the resultant regions are called transmission defects. A second reason for hyperfluorescence can be the abnormal accumulation of dye either within the vascular space of abnormalities in the vasculature or in extravascular leakage. An obvious example of excessive vessels is the presence of choroidal neovascularization. Leakage can also occur from vessels. By convention, leakage of fluorescein into a space results in pooling of the fluorescein while leakage into a tissue is called staining.
There are two main causes for hypofluorescence: Either there is less fluorescein present or there is something blocking our view of the fluorescein (Tables 9.1 and 9.2).
9.10.1 Drusen
Drusen have been divided into a number of groups chiefly based on their size and appearance. Drusen may be large, >125 mm (about the diameter of an arcade vein near the optic disk), intermediate 63–124 mm, or small, <63 mm. The retinal pigment epithelium often is thinner over the surface of a druse, producing a transmission defect. Smaller drusen can sometimes appear bright early in a fluorescein angiogram. On occasion there may be a myriad of small drusen, termed cuticular drusen. During fluorescein angiography, basal laminar drusen appear as a “starry sky” of thousands of points of light. Not uncommonly cuticular drusen may be associated with a deposition of yellow subretinal material that mimics vitelliform dystrophy. Patients with this deposition of material frequently have fluorescein leakage that may mimic CNV (Fig. 9.4).
A particular distribution of small drusen is seen in malattia leventinese, an inherited disorder traced back to descendents from a Swiss valley. These eyes have a radial distribution of small drusen associated with pigmentary changes. Soft drusen usually are not readily visible in the early phases of a fluorescein angiogram, but may stain later (Fig. 9.1). Subretinal drusenoid deposits, also known as reticular pseudodrusen, are subretinal drusen that do
9.9Indocyanine Green Angiographic not show significant fluorescein angiographic findings
Interpretation |
[26]. Drusen composition may affect both fluorescein |
|
[27] and indocyanine green staining [28], but there is no |
The phases of an indocyanine green angiogram are |
practical implication of these considerations yet. |
somewhat similar to a fluorescein angiogram. The |
The outermost bright line is attributed to the RPE/ |
early phases of the indocyanine green angiogram show |
Bruch’s membrane layer, but since the choriocapillaris |
both choroidal and retinal vascular filling, which occur |
is integrally involved with the outer Bruch’s membrane, |
in parallel, but not exactly in phase in that the chor- |
it is probably imaged as well. Drusen lift up the RPE, |
oid starts to fill first. The transition to the venous phase |
and in the case of large soft drusen, Bruch’s membrane |
happens more quickly in the choroid than in the ret- |
may be visualized. Drusen have a relatively homoge- |
ina. Unlike with fluorescein, there is normally a small |
neous composition. The exception to this occurs if there |
amount of background staining with ICG. Because of |
is shadowing; in that case, the inner composition of a |
9 Fundus Imaging of AMD |
151 |
|
|
Fig. 9.4 This patient has numerous small drusen with some larger drusen visible in the posterior pole (upper left). There also is a subtle collection of light yellow material in the central fovea. The fluorescein angiogram shows innumerable small drusen that are hyperfluorescent (upper right) [24]. There is an increased amount of fluorescence in the central macula, which may mimic
that from choroidal neovascularization. Bottom, the optical coherence tomography scan shows the mound-like elevations of the drusen, but no neovascularization. There is subretinal fluid, which is a very common finding in patients with early detachment related to cuticular drusen [25].
large druse would have a gradient of reflectivity. The |
and intraretinal fluids accumulate more readily over |
|
OCT of CNV under the RPE shows reflective elements |
areas that have concurrent atrophy of the RPE. |
|
and a heterogeneous composition. Drusen can have a |
|
|
variety of configurations under the RPE, which may |
|
|
9.11 Pigmentary Abnormalities |
||
affect their appearance by ophthalmoscopy. In the past, |
||
these were called reticular pseudodrusen, but recently, |
Including Geographic Atrophy |
|
they were found to be drusen above the RPE. Like |
|
|
drusenoid collections under the RPE, they are homoge- |
One important ocular characteristic that is a risk factor |
|
neous. CNV on the surface of the RPE is generally |
for the development of choroidal neovascularization is |
|
much thicker and is not homogeneous. Exudation from |
focal hyperpigmentation. Histopathologic correlation |
|
CNV can lead to accumulation of fluid in or under the |
of focal hyperpigmentation has demonstrated detached |
|
retina if the volume of fluid produced exceeds the |
cells containing pigment in the subretinal space. These |
|
regions ability to remove fluid. For this reason the |
areas of focal hyperpigmentation also display focal |
|
absence of fluid does not necessarily mean the absence |
hyperautofluorescence and increased absorption of |
|
of leakage. Excessive fluid in the retina can cause thick- |
infrared light, suggesting these cells contain lipofuscin |
|
ening or when more significant amount of fluid accu- |
[29]. In addition, the presence of focal hyperpigmenta- |
|
mulates, cystoid spaces become visible. Both subretinal |
tion was found to be highly correlated with retinal |
152 |
R.F. Spaide |
|
|
Fig. 9.5 Top, a patient with classic CNV who shows subretinal blood (left), early hyperfluorescence (middle), and late leakage (right). Bottom, a patient with predominantly
occult CNV: (left) a diffuse elevation at the level of the RPE; (middle) early hypofluorescence; (right) late, poorly defined hyperfluorescence
vascular anastomosis to the endovascular process in the fellow eye [29]. Focal hyperpigmentation has two main OCT correlates: the first is localized thickening of the RPE layer and the second is small hyperreflective aggregates in the outer retina.
An additional pigmentary alteration is atrophy, which can occur in sharply defined areas of severe atrophy, known as geographic atrophy, or in less well-defined, more granular regions of less severe atrophy known as non-geographic atrophy. The outer borders of a region of geographic atrophy are slightly hyperpigmented at the level of the retinal pigment epithelium, and this hyperpigmented zone occasionally is hyperautofluorescent [30], suggesting as one of many possibilities, the cells bordering areas of geographic atrophy may contain excessive lipofuscin. During fluorescein angiography, there is a welldemarcated region of late hyperfluorescence without signs of leakage. This hyperfluorescence is from visible staining of deeper layers of the eye, such as the sclera, without normal blockage by overlying pigment. The angiographic appearance early in the fluorescein depends on the amount of retained choriocapillaris. Generally geographic atrophy shows increasing fluorescence during the early and midphases of the fluorescein angiogram. More austere forms of geographic atrophy show early fluorescence of the
larger choroidal vessels and a lack of overlying choriocapillaris. Geographic atrophy appears hypofluorescent during indocyanine green angiography because of the lack of choriocapillaris and because of the lack of an overlying retinal pigment epithelium, which shows normal physiologic staining late in the angiographic sequence.
9.12Neovascular AMD
Vascular ingrowth causes physiologic and architectural alteration in the macular region, and this alteration can be detected and evaluated with angiography (Fig. 9.5). The vessels usually grow in the inner portion of Bruch’s membrane, although they may penetrate into the subretinal space. The angiographic appearance of choroidal neovascularization is governed by the location, density, and maturity of the new vessels as well as the amount and character of the intervening tissue. CNV manifesting as delineated hyperfluorescence early in the angiographic sequence with leakage later is termed classic, while vessels that are not particularly hyperfluorescent that show leakage late are termed “occult.” At one time occult CNV was divided into late leakage of undetermined source or as a fibrovascular pigment epithelial detachment. With
9 Fundus Imaging of AMD |
153 |
|
|
Fig. 9.6 (Upper left) This patient has choroidal neovascularization with retinal vessels that appear to descend to anastomose with the neovascular process. (Top right) The fluorescein angiogram demonstrates the CNV, but not the anastomosis. (Lower left)
The indocyanine green angiogram shows evidence of retinal vascular anastomosis with the underlying CNV. (Lower right) An enlargement with contrast enhancement more clearly shows the anastomotic vessels
the advent of improved imaging, particularly optical coherence tomography, nearly all patients with occult CNV prove to have a fibrovascular PED.
Generally CNV seen as classic during fluorescein angiography is not imaged as dramatically by indocyanine green angiography. Classic CNV does not show prominent leakage during ICG angiography, probably because of the higher protein binding of ICG. Occult CNV, either fibrovascular PEDs or late leakage of undetermined source, shows a variety of patterns during ICG angiography. Curiously, areas of CNV that appear very poorly defined during fluorescein angiography can be well defined during ICG angiography. Most regions of occult CNV appear as relatively large plaques during ICG angiography. Some occult lesions show minimal if any abnormalities during ICG angiography.
Indocyanine green angiography is indispensible in three main conditions.
–Retinal vascular anastomosis to CNV is usually easier to demonstrate with ICG angiography as compared with fluorescein angiography (Fig. 9.6). While this may not be important for anti-vascular endothelial growth factor (VEGF) based therapies, it probably is an indication that thermal laser photocoagulation would prove to be unsuccessful.
–The second main use of ICG angiography is to differentiate central serous chorioretinopathy (CSC) from occult CNV. Eyes with CSC have dilated vessels in the filling phases, multifocal choroidal vascular hyperpermeability in the midphases, and silhouetting of the larger vessels in the later portions of the angiogram. Occult CNV shows a
154 |
R.F. Spaide |
|
|
Fig. 9.7 Polypoidal choroidal vasculopathy demonstrating vascular channels (left) with small aneurismal changes at the lesion’s outer border; 18 months later, the aneurismal changes became much larger and were associated with serosanguineous exudation
Fig. 9.8 This Asian patient had an extensive region of neovascularization, yet retained 20/30 acuity. (Upper right) The vascular network is not readily visible, but the aneurysmal changes are (arrowheads). (Upper right) Indocyanine green angiography shows prominent aneurysmal dilations. Visualization of the vascular network is partially obscured by the
simultaneous visualization of the underlying choroidal vessels. (Lower left) The vascular network is easier to visualize in the midframes of the angiogram while the aneurysmal dilations remain readily visible (arrowheads). (Lower right) There is late staining of the walls of the aneurysmal dilations (arrowheads) and washout of the dye centrally
